期刊文献+

非洛地平联合阿托伐他汀钙对颈动脉内-中膜厚度的影响

The Effect of Combination of Felodipine and Atorvastatin on Carotid Artery Intima-media the Thickness in Essential Hypertension
下载PDF
导出
摘要 目的:研究非洛地平联合阿托伐他汀钙对高血压颈动脉内-中膜厚度(IMT)的影响。方法:将原发性高血压患者84例,随机分为实验组42例和对照组42例,对照组使用非洛地平5mg,1次/d,实验组在对照组基础上,加用阿托伐他汀钙20mg,1次/晚,治疗12个月,比较两组IMT,血压,空腹血糖及血脂水平。结果:实验组治疗12个月后,颈动脉IMT、收缩压、TG、TC、LPL-C均显著降低,治疗后的IMT与治疗前及与对照组治疗后的IMT比较,差异均有统计学意义(P<0.05)。两组间血糖、心率比较差异无统计学意义。结论:高血压患者服用非洛地平联合阿托伐他汀钙治疗能更好地延缓IMT进展。 Objective : To study the effect of combination of Felodipine and atorvastatin on carotid artery intima - media thickness (IMT) in patients with essential hypertension. Methods:Eighty -four patients with essential hypertension were randomly divided into test and control groups. The control group was treated with Felodipine and the test group was treated with atorvastatin 20mg every night in addition to Felodipine for twelve months. The differences were observed between two groups. Results: After twelve months of therapy, in test group, carotid artery IMT, systolic blood pressure, diastolic blood pressure, serum triglyeeride, total cholesterul and low - density lipoprotein cholesterol significantly decreased. There were significant difference pre - treatment and after treatment, and significant differences between test group and control group. Conclusion : The combination of Felodipine and atorvastatin can delay increase in carotid artery intima - media thickness of patients with essential hypertension.
出处 《长治医学院学报》 2009年第6期427-429,共3页 Journal of Changzhi Medical College
关键词 高血压 动脉硬化 非洛地平 血管内膜 阿托伐他汀钙 Hypertension Arteriosclerosis Felodipine Tunica intima Atrovastatin
  • 相关文献

参考文献6

二级参考文献32

  • 1ShengDENG,Pan-yueDENG,Jun-linJIANG,FengYE,JingYU,Tian-lunYANG,Han-wuDENG,Yuan-jianLI.Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats[J].Acta Pharmacologica Sinica,2004,25(12):1633-1639. 被引量:15
  • 2张文斌,宋筱筱,傅国胜,蔡思宇.他汀类药物临床研究进展[J].心血管病学进展,2006,27(1):79-82. 被引量:40
  • 3周滔,周胜华,祁述善,沈向前,曾高峰,周宏年.阿托伐他汀对单核细胞髓过氧化物酶和过氧化物增殖活化剂受体γ表达的影响[J].临床心血管病杂志,2007,23(1):59-61. 被引量:4
  • 4Ikeda Y,Yong LH,Lefer AM.Rosuvastatin,a new HMGCoA reductase inhibitor,protects ischemic reperfused myocardium in normocholesterolemic rats[J].J Cardiovasc Pharmacol,2003,41:649-656.
  • 5Bell RM,Yellon DM.Atorvastatin,administered at the onset of reperfusion,and independent of lipid lowering,protects the myocardium by upregulating a prosurvival pathway[J].J Am Coll Cardiol,2003,41:508-515.
  • 6Yamakuchi M,Greer JJ,Cameron SJ.HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size[J].Circ Res,2005,96:1185-1192.
  • 7Brennan ML,Pennms MS,Van Lente F,et al.Prognostic value of myeloperoxidase in patients with chest pain[J].N Engl J Med,2003,349:1595-1604.
  • 8Rogler G,Lackner KJ,Schmitz G.Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro[J].Am J Cardiol,1995,76:114A-116A.
  • 9Park YS,Guijarro C,Kim Y,et al.Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats[J].Am J Kidney Dis,1998,31:190-194.
  • 10Yoshida M,Sawada T,Ishii H,et al.HMG-CoA reductase inhibitor modulatesmonocyte-endothelial cell interaction under physiological flow conditions invitro:involvement of Rho GTPase-dependent mechanism[J].ArteriosclerThromb Vasc Biol,2001,21:1165-1171.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部